Alumis Inc./$ALMS
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Alumis Inc.
Alumis Inc is a clinical-stage biopharmaceutical company focused on identifying, acquiring, and accelerating the development and commercialization of transformative medicines for autoimmune disorders. The Company leverages its proprietary precision data analytics platform, biological insights, and a team of experts with deep experience in precision medicine drug discovery, development, and immunology, to create medicines that significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. Company pipeline includes: ESK-001, TYK2, A-OO5, IRF5.
Ticker
$ALMS
Sector
Primary listing
Employees
226
Headquarters
Website
Alumis Inc. Metrics
BasicAdvanced
$469M
-
-$3.81
-
-
Price and volume
Market cap
$469M
52-week high
$10.49
52-week low
$2.76
Average daily volume
629K
Financial strength
Current ratio
6.048
Quick ratio
5.775
Long term debt to equity
7.154
Total debt to equity
7.99
Profitability
EBITDA (TTM)
-416.041
Gross margin (TTM)
100.00%
Net profit margin (TTM)
-1,134.47%
Operating margin (TTM)
-2,091.19%
Effective tax rate (TTM)
3.63%
Revenue per employee (TTM)
$90,000
Management effectiveness
Return on assets (TTM)
-59.84%
Return on equity (TTM)
-66.35%
Valuation
Price to revenue (TTM)
13.461
Price to book
0.97
Price to tangible book (TTM)
1.08
Price to free cash flow (TTM)
-0.778
Free cash flow yield (TTM)
-128.55%
Free cash flow per share (TTM)
-5.798
Growth
Earnings per share change (TTM)
-95.32%
Bulls say / Bears say
Completion of patient enrollment in the global LUMUS Phase 2b trial of ESK-001 for systemic lupus erythematosus marks a critical pipeline milestone and positions Alumis for a topline readout in Q3 2026.
Positive 52-week data from the Phase 2 OLE of ESK-001 in moderate-to-severe plaque psoriasis demonstrated sustained PASI 90 and PASI 100 responses with no new safety signals, supporting the program’s best-in-class potential.
Phase 1 data presentations at ACTRIMS Forum 2025 showed A-005’s CNS penetration and potent TYK2 inhibition in both immune and CNS cells, enabling a planned Phase 2 multiple sclerosis trial in H2 2025.
R&D expenses surged to $108.8 million in Q2 2025, more than doubling year-over-year and significantly increasing cash burn.
With GAAP revenue of only $2.7 million in Q2 2025, Alumis remains heavily reliant on collaboration income and non-dilutive funding sources.
A $187.9 million bargain purchase gain from the ACELYRIN merger inflated net income to $59.3 million in Q2 2025, masking underlying operating losses.
Data summarised monthly by Lightyear AI. Last updated on 6 Oct 2025.
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Alumis Inc. stock?
Alumis Inc. (ALMS) has a market cap of $469M as of October 26, 2025.
What is the P/E ratio for Alumis Inc. stock?
The price to earnings (P/E) ratio for Alumis Inc. (ALMS) stock is 0 as of October 26, 2025.
Does Alumis Inc. stock pay dividends?
No, Alumis Inc. (ALMS) stock does not pay dividends to its shareholders as of October 26, 2025.
When is the next Alumis Inc. dividend payment date?
Alumis Inc. (ALMS) stock does not pay dividends to its shareholders.
What is the beta indicator for Alumis Inc.?
Alumis Inc. (ALMS) does not currently have a Beta indicator.